544 related articles for article (PubMed ID: 19074844)
21. Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents.
Limaverde-Sousa G; Sternberg C; Ferreira CG
Cancer Treat Rev; 2014 May; 40(4):548-57. PubMed ID: 24360358
[TBL] [Abstract][Full Text] [Related]
22. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
[TBL] [Abstract][Full Text] [Related]
23. Molecular Mechanisms of Resistance to Anti-Angiogenic Drugs.
Filippelli A; Ciccone V; Donnini S; Ziche M; Morbidelli L
Crit Rev Oncog; 2021; 26(2):39-66. PubMed ID: 34347972
[TBL] [Abstract][Full Text] [Related]
24. Redefining the target: chemotherapeutics as antiangiogenics.
Miller KD; Sweeney CJ; Sledge GW
J Clin Oncol; 2001 Feb; 19(4):1195-206. PubMed ID: 11181686
[TBL] [Abstract][Full Text] [Related]
25. Vessel pruning or healing: endothelial metabolism as a novel target?
Cantelmo AR; Pircher A; Kalucka J; Carmeliet P
Expert Opin Ther Targets; 2017 Mar; 21(3):239-247. PubMed ID: 28081641
[TBL] [Abstract][Full Text] [Related]
26. Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.
Pircher A; Jöhrer K; Kocher F; Steiner N; Graziadei I; Heidegger I; Pichler R; Leonhartsberger N; Kremser C; Kern J; Untergasser G; Gunsilius E; Hilbe W
Oncotarget; 2016 Apr; 7(15):20109-23. PubMed ID: 26956051
[TBL] [Abstract][Full Text] [Related]
27. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
Kerbel RS
Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
[TBL] [Abstract][Full Text] [Related]
28. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors.
Folkins C; Man S; Xu P; Shaked Y; Hicklin DJ; Kerbel RS
Cancer Res; 2007 Apr; 67(8):3560-4. PubMed ID: 17440065
[TBL] [Abstract][Full Text] [Related]
29. Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies.
Pluda JM
Semin Oncol; 1997 Apr; 24(2):203-18. PubMed ID: 9129690
[TBL] [Abstract][Full Text] [Related]
30. Antiangiogenesis by chemotherapeutic agents.
Ribatti D; Vacca A; Merchionne F; Presta M
Mini Rev Med Chem; 2005 Mar; 5(3):313-7. PubMed ID: 15777265
[TBL] [Abstract][Full Text] [Related]
31. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
32. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
33. Marine-derived angiogenesis inhibitors for cancer therapy.
Wang YQ; Miao ZH
Mar Drugs; 2013 Mar; 11(3):903-33. PubMed ID: 23502698
[TBL] [Abstract][Full Text] [Related]
34. Anti-angiogenic therapies in cancer: achievements and open questions.
Ruegg C; Mutter N
Bull Cancer; 2007 Sep; 94(9):753-62. PubMed ID: 17878094
[TBL] [Abstract][Full Text] [Related]
35. Synopsis of angiogenesis inhibitors in oncology.
Ellis LM; Liu W; Fan F; Jung YD; Reinmuth N; Stoeltzing O; Takeda A; Akagi M; Parikh AA; Ahmad S
Oncology (Williston Park); 2002 May; 16(5 Suppl 4):14-22. PubMed ID: 12102576
[TBL] [Abstract][Full Text] [Related]
36. Off-tumor target--beneficial site for antiangiogenic cancer therapy?
Cao Y
Nat Rev Clin Oncol; 2010 Oct; 7(10):604-8. PubMed ID: 20683436
[TBL] [Abstract][Full Text] [Related]
37. Tumor vasculature and microenvironment normalization: a possible mechanism of antiangiogenesis therapy.
Huang G; Chen L
Cancer Biother Radiopharm; 2008 Oct; 23(5):661-7. PubMed ID: 18986217
[TBL] [Abstract][Full Text] [Related]
38. Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib.
Ma J; Waxman DJ
Clin Cancer Res; 2009 Jan; 15(2):578-88. PubMed ID: 19147763
[TBL] [Abstract][Full Text] [Related]
39. Challenges facing antiangiogenesis therapy: The significant role of hypoxia-inducible factor and MET in development of resistance to anti-vascular endothelial growth factor-targeted therapies.
Mahdi A; Darvishi B; Majidzadeh-A K; Salehi M; Farahmand L
J Cell Physiol; 2019 May; 234(5):5655-5663. PubMed ID: 30515806
[TBL] [Abstract][Full Text] [Related]
40. Trends and Challenges in Tumor Anti-Angiogenic Therapies.
Jászai J; Schmidt MHH
Cells; 2019 Sep; 8(9):. PubMed ID: 31540455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
